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Backgrounds: Glypican-3(GPC3) has been implicated in tumor development and progression for several years.
However, the prognostic significance of GPC3 expression in patients with hepatocellular carcinoma (HCC) is
controversial. We performed a meta-analysis of available studies to assess whether GPC3 can be used as a prognostic
factor in patients with HCC.
Methods: We searched PubMed and Ovid EBM Reviews databases and evaluated the reference list of relevant articles
for studies that assessed the prognostic relevance of GPC3 in patients with HCC. Meta-analysis was performed using
hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (95% CIs) as effect measures.
Results: A meta-analysis of eight studies included 1070 patients was carried out to evaluate the association between
GPC3 and overall survival (OS) and disease-free survival (DFS) in HCC patients. The relation between GPC3 and tumor
pathological features was also assessed. Our analysis results indicated that high GPC3 expression predicted poor OS
(HR: 1.96, 95% CI: 1.51–2.55) and DFS (HR: 1.99, 95% CI: 1.57-2.51) of patients with HCC. GPC3 overexpression was
significantly associated with high tumor grade (OR: 3.30, 95% CI: 2.04–5.33), late TNM stage (OR: 2.26, 95% CI: 1.00–5.12),
and the presence of vascular invasion (OR: 2.43, 95% CI: 1.23–4.82).
Conclusions: GPC3 overexpression indicates a poor prognosis for patients with HCC, and it may also have predictive
potential for HCC invasion and metastasis.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon devastating neoplasm worldwide with increasing
incidence over the last several decades across the world
[1]. Meanwhile, its third cancer-related mortality rate
among varieties of cancers indicates the poor prognosis.
Operative resection and liver transplantation are consid-
ered potential curative treatments for HCC; however,
the overall prognosis of HCC patients remains dismal
because of high rate of recurrence after curative resec-
tion [2]. Therefore, it is important to identify molecular
markers for prognosis of patient survival and/or tumor
recurrence, which would help clinician to adopt prevent-
ive strategies for patients at high risk of recurrence.* Correspondence: lisq@medmail.com.cn
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unless otherwise stated.Glypican-3 (GPC3), a member of the glypican family of
heparan-sulfate proteoglycans (HSPGs), is bound to the
plasma membrane through a glycosyl phosphatidylinositol
(GPI) anchor. GPC3 is highly expressed in HCC but not
in normal adult tissue. It has been discovered as a good
serologic and immunohistochemical diagnostic marker for
HCC in recent years [3]. GPC3 would be a more reliable
tumor marker that could allow an earlier diagnosis of
HCC when compared with serum alpha-fetoprotein [4,5].
Recently, several studies showed that GPC3 can stimulate
the growth, migration and adhesion of HCC cells by up-
regulating autocrine/paracrine canonical Wnt signaling
[6-10]. Moreover, Ho et al identified that GPC3, as one of
leading genes, was distinctly expressed in liver CD90+
cancer stem cells, which plays an important role in
tumor progression and metastasis [11]. Thus, GPC3 ex-
pression may function as a new and independent prog-
nostic marker for HCC patients. However, conflicting
data have emerged regarding the ability of GPC3 tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fore, it is necessary to conduct a meta-analysis to system-
atically and comprehensively understand the prognostic
value of GPC3 in HCC.
In this study, we aimed to assess the prognostic signifi-
cance of GPC3 for OS and DFS in HCC patients by pool-
ing outcomes from the available data. In addition, the
correlation between GPC3 expression and tumor patho-
logical features (such as tumor grade, stage, or vascular in-
vasion) was also examined.
Material and methods
Identification and selection of studies
Study objectives
The primary endpoint was to evaluate patients’ OS and
DFS based on their GPC3 profiles. The secondary end-
point was to assess the relation between GPC3 expres-
sion and tumor pathological features (such as tumor
grade, stage, or vascular invasion, etc.).
Search strategy
PubMed and Ovid EBM Reviews databases were system-
atically searched in August 2013 without time restric-
tion. The search strategy was based on combinations of
the following terms: (GPC3 [MESH] or GPC3 [TEXT
WORD]) AND (carcinoma, hepatocellular [MESH] or
HCC [TEXT WORD]). Reports in English were eligible
for inclusion. The reference list was also checked for
relevant articles. Investigators were contacted and asked
to supply additional data when key information relevant
to the meta-analysis was missed.
Inclusion criteria of studies
All studies included in this meta-analysis must meet the
following criteria: (1) GPC3 expression was measured by
immunohistochemistry (IHC); (2) The relationship be-
tween GPC3 and DFS and/or OS of patients with HCC
was evaluated; (3) Sample size was greater than 20.
Definitions and data extraction
OS was defined as the interval between the medical
treatment (including liver resection, liver transplant-
ation or radiofrequency ablation, etc.) and the death or
the last observation of patients. DFS was measured from
the date of treatment to the date of detection of tumor-
recurrence. Tumor vascular invasion was defined as pres-
ence of either macro- or microscopic vascular invasion.
The histologic grade of tumor was assigned according to
the Edmondson Steiner grading system, and tumors were
grouped as well/moderately (I/II) and poorly (III/IV) de-
grees of differentiation [12]. The clinical stage of tumors
was determined according to the tumor-nodes-metastasis
(TNM) classification system of the International Union
against Cancer by the American Joint Committee (UICC,6th edition) [13]. Tumor multifocality was defined as
tumor number greater than 2. All data extractions were
performed separately by XWK and QCY. Disagreements
were resolved by discussion.
Qualitative assessment
The quality assessment of included studies was evaluated
by the modified Newcastle–Ottawa quality assessment
scale with moderate modifications (see the ‘List of Saints’
section) [14,15]. A score of 0-9 (labeled as stars) was used
to indicate the quality of each study. Studies labeled with
six or more stars were considered to be high quality.
Newcastle-Ottawa quality assessment scale
Selection
(1) Representativeness of the exposed cohort(a) Truly representative of the average HCC patients
in the community*
(b) Somewhat representative of the average HCC
patients in the community*
(c) Selected group of users (e.g., nurses, volunteers)
(d) No description of the derivation of the cohort
(2) Selection of the non exposed cohort
(a) Drawn from the same community as the
exposed cohort*
(b) Drawn from a different source
(c) No description of the derivation of the non
exposed cohort
(3) Ascertainment of exposure (Proof of HCC and
glypican-3 measurement)
(a) Secure record (e.g., surgical records)*
(b) Structured interview *
(c) Written self report
(d) No description
(4) Demonstration that outcome of interest was not




(1) Comparability of cohorts on the basis of the design
or analysis
(a) Study controls for recurrence or metastasis*
(b) Study controls for any additional factor
(Age, gender, grade, alpha-fetoprotein level, etc.)*Outcome




(2) Was follow-up long enough for outcomes to occur?
(Death or recurrence)
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(b) No
(3) Adequacy of follow up of cohorts
(a) Complete follow up – all subjects accounted for*
(b) Subjects lost to follow up unlikely to introduce
bias – small number lost – (25%) follow up, or
description provided of those lost)*
(c) Follow up rate (<75%) and no description of
those lost
(d) No statement
A study can be awarded a maximum of one star (*) for
each numbered item within the Selection and Outcome
categories. A maximum of two stars can be given for
Comparability. Underlined and quoted phrases are pro-
vided in the scale to allow for adjustment to particular
studies. Italicised phrases indicate our interpretation of
the question relevant to this study.
Quantitative analysis (meta-analysis)
Statistical methods
Included studies were divided into two groups for analysis:
those with data regarding OS and those regarding DFS.
Data on the prognostic ability of GPC3 overexpression for
OS and DFS were pooled across studies. For the quantita-
tive aggregation of the survival results, hazard ratios (HRs)
and their associated standard errors (SEs) were pooled to
give the effective value. When these statistical variables
were not directly provided in the original articles, they
were calculated from available numerical data using
methods reported by Parmar et al. [16]. For the pooled
analysis of the relation between GPC3 and tumor patho-
logical features, odds ratios (OR) and their 95% confidence
intervals (95% CIs) were pooled to give the effective value.
In this study, the cut-off value for “high versus low”
GPC3 expression was determined by investigators of each
study. A uniform of “high” GPC3 cut-off value was not ob-
tained in this study. A HR >1 implies a worse prognosis in
the group with GPC3 overexpression. An OR > 1 indicated
higher probability for high tumor grade, later stage or the
presence of vascular invasion in the group with GPC3
overexpression. The point estimate of the HR or OR was
considered statistically significant at the p < 0.05 level if
the 95% CI did not include the value 1. In the course of
data pooling, we measured the extent of inconsistency
among the results by using the I squared (I2) statistic and
tested the heterogeneity using chi-square (χ2) test. Because
this test has poor power in the case of few studies, we con-
sidered both the presence of significant heterogeneity at
the 10% level of significance and the value of I2 exceeding
50% as an indicator of significant heterogeneity [17]. The
random-effects model was used if there was heterogeneity
between studies; otherwise, the fixed-effects model was
used [17]. Subgroup analyses that considered morehomogeneous studies were performed to identify the best
cut-off value of high GPC3 to predict the prognosis of
HCC. To determine the extent to which the combined
risk estimate might be affected by individual studies,
sensitivity analysis was performed by a repetition of
the original analysis with the exclusion of the most
heavily weighted study. Analysis on main results was
performed by using Review Manager Version 5.0 software
(Copenhagen: The Nordic Cochrane Centre; The Cochrane
Collaboration, 2008).
Results
Selection and characteristics of studies
308 records regarding the association of GPC3 and HCC
were identified via the initial literature search. 295 studies
were excluded after screening the titles or abstracts as they
were review articles, abstracts, experiment research, dupli-
cate reports, reports in language other than English or
studies irrelevant to the current analysis. 13 relevant stud-
ies were selected for detailed evaluation, 4 were further
excluded after full assessment due to lacking relevant sur-
vival data. After careful evaluation by applying our inclu-
sion criteria, a total of 9 eligible studies were identified
[18-26]. Of the 9 studies, 2 were reported by the same
study center [22,23], and the patients were partly overlap-
ping in the 2 studies. To avoid duplicate counting, only 1
study with more complete data was selected [23]. There-
fore, eight studies with 1070 patients which met our inclu-
sion criteria were selected for our meta-analysis finally
[18-21,23-26]. Four studies were performed in China
[20,23,25,26], one in Taiwan [21], and three in Japan
[18,19,24]. Surgical resection as initial treatment for HCC
was reported in 7 studies [18-21,24-26], and liver trans-
plantation(LT) reported in one study [23]. Sample sizes
ranged from 31 to 362. Mean or median age ranged from
43 to 65.5 years. The number of male population varied
from 29 to 324. The number of HCC patients with vascu-
lar invasion ranged from 14 to 107.
DFS was reported or estimated in seven studies
[18-21,23-25], whereas OS was only presented in six studies
[18-20,24-26]. The scores of study quality assessed by
Newcastle-Ottawa quality assessment scale ranged from 5
to 8, with a mean of 6.25. A high score indicated better
methodology. HRs were recorded for each study using
available data or the methods described above. The number
of HCC patients with high GPC3 expression ranged from
20 to 228. The basic features of the eight studies were sum-
marized in Table 1.
All these eight studies detected GPC3 by IHC. Regar-
ding antibody type, mouse monoclonal antibody was most
common use. The immunohistochemical results were
evaluated according to the area or percentage of GPC3-
positive staining cells in five studies, positive area and ex-
pression intensity in one study, and image analysis in one
Table 1 Baseline characteristics of the studies in the meta-analysis








Shirakawal [18] 2009 Japan SR 107(85) 63.6/60.2 57 12/95
Yorita [19] 2010 Japan SR 194(142) NA 108 179/15
Su [20] 2012 China SR 61(55) 48.0 NA NA
Yu [21] 2012 Taiwan SR 100(90) 51.39 23 NA
Wang [23] 2012 China LT 31(29) 49 16 6/25
Chen [24] 2013 Japan SR 55(36) 65.5 /63.5 NA NA
Fu [25] 2013 China SR 160(140) 50.2 30 123/37
Liang [26] 2013 China SR 362(324) 43-50 53 NA




Outcome indexes Multi-variate analysis Patients with High GPC3 Study quality (Points) “high” GPC3
cut-off level
Shirakawal [18] 92/15 42 OS/DFS Yes 87 8/9 >10 %
Yorita [19] 82/112 31.2 OS/DFS Yes 97 7/9 ≥20 %
Su [20] 45/16 NA OS/DFS Yes 32 5/9 >10 %
Yu [21] NA 66.5 DFS NA NA 5/9 +3*
Wang [23] 12/19 24 DFS NA 20 5/9 >10 %
Chen [24] NA 66 OS/DFS yes 28 6/9 >10 %
Fu [25] NA 34.5 OS/DFS yes 109 8/9 >25 %
Liang [26] NA 34.5 OS NA 228 6/9 >0 %
Studies (Reference) Antibody type Detection method Evaluation method GPC3 staining
Shirakawal [18] Mouse Monoclonal antibody IHC Positive area Cytoplasm membrane
Yorita [19] Monoclonal antibody IHC: Histofine Her2 kit Positive area Cytoplasm membrane
Su [20] Mouse Monoclonal antibody IHC: Chemmate EnVision/Mo&Rb detection kit Positive area
and intensity
Cytoplasm membrane
Yu [21] NA IHC NA Cytoplasm membrane
Wang [23] Monoclonal antibody IHC Positive area Cytoplasm membrane
Chen [24] Rabbit monoclonal antibody IHC Positive area cytoplasm peri- canalicular
Fu [25] Mouse Monoclonal antibody IHC Percentage of positive cells Cytoplasm membrane
Liang [26] NA IHC: two-step protocol (DakoCytomation, Glostrup, Denmar) TMAJ Image application Cytoplasm membrane
SR, surgical resection; LT, livertransplantation; NA, not available; IHC, immunohistochemistry; OS, overall survival; DFS, disease-free survival.
Tumor vascular invasion was defined as presence of either macro- or microscopic vascular invasion (including portal vein invasion, etc.).
High glypican-3 cut-off level was scored according to the percentage of positive tumor cells by immunohistochemical staining.

























Heterogeneity: Tau² = 0.00; Chi² = 1.37, df = 5 (P = 0.93); I² = 0%































Hazard Ratio Hazard Ratio
IV, Random, 95% CI
0.01 0.1 1 10 100
Favours prolonged OS Favours shortened OS
Figure 1 Meta-analysis of the association between glypican-3(GPC3) overexpression and overall survival (OS) of patients with HCC.
Results are presented as individual and pooled hazard ratio (HR), and 95% confidence interval (CI).
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with some detected on the cell membranes in all included
studies. The cut-off values of high GPC3 expression were
0% [26], 10% [18,20,23,24], 20% [19], and 25% [25] of posi-
tive tumor cells by IHC staining reported in the included
studies, respectively (Table 1).
GPC3 expression and OS in HCC patients
Six studies reported data on GPC3 expression and OS in
HCC initially treated by surgical resection [18-20,24-26].
High GPC3 expression was significantly associated with
poor OS in all studies. Pooled data from all these studies
suggested that high GPC3 expression was significantly
correlated with poor OS with a pooled HR estimate of
1.96 (95% CI: 1.51–2.55, p = 0.000; Figure 1), without any









Heterogeneity: Chi² = 9.07, df = 6 (P = 0.17); I² = 34%




































Figure 2 Meta-analysis of the association between glypican-3(GPC3) o
HCC. Results are presented as individual and pooled hazard ratio (HR), andGPC3 expression and DFS in HCC patients
Seven studies reported the relationship between GPC3
expression and DFS in HCC. Six studies [18-21,23-25]
presented the information of GPC3 expression corre-
lated with DFS in HCC initially treated by surgical resec-
tion. High GPC3 expression was significantly associated
with poor DFS in five studies. Pooled data from all seven
studies showed that high GPC3 expression was signifi-
cantly correlated with poor DFS with a pooled estimate
HR of 1.99 [95% CI: 1.57–2.51, p = 0.000; Figure 2], and
without significant heterogeneity in the data (χ2 =9.07,
I2 = 34%, p = 0.17).
GPC3 expression and tumor pathological features
High GPC3 expression tended to be correlated with high
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verexpression and disease-free survival (DFS) of patients with








Heterogeneity: Chi² = 4.56, df = 3 (P = 0.21); I² = 34%





































High GPC3 Low GPC3 Odds Ratio Odds Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100








Heterogeneity: Tau² = 0.36; Chi² = 6.50, df = 3 (P = 0.09); I² = 54%





































High GPC3 Low GPC3 Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100








Heterogeneity: Tau² = 0.24; Chi² = 6.19, df = 3 (P = 0.10); I² = 52%





































High GPC3 Low GPC3 Odds Ratio Odds Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100








Heterogeneity: Chi² = 0.91, df = 3 (P = 0.82); I² = 0%
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Heterogeneity: Tau² = 0.64; Chi² = 10.63, df = 3 (P = 0.01); I² = 72%
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Figure 3 Meta-analysis of the correlation between glypican-3(GPC3) overexpression and high tumor grade (3A), tumor TNM stage (3B),
vascular invasion (3C), tumor size≥ 5 cm (3D) and tumor multifocality (3E) in HCC. Results are presented as individual and pooled odds
ratio (OR), and 95% confidence interval (CI).
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was observed in three studies [18,19,23]. Pooled data from
all four studies showed a significant correlation between
high GPC3 expression and high tumor grade (OR: 3.30,
95% CI: 2.04–5.33, p = 0.000; Figure 3A).
Four studies also provided data on the correlation of
GPC3 with tumor TNM stage [18-20,23]. High GPC3
expression tended to be correlated with late tumor
stage (III + IV) in 3 studies [19,20,23], and a statistical
significant correlation was observed in two studies
[19,20]. Pooled data from all four studies showed a sig-
nificant correlation between high GPC3 expression and
late TNM stage (OR: 2.26, 95% CI: 1.00–5.12, p = 0.05;
Figure 3B).
Four studies reported data on GPC3 expression and
vascular invasion in HCC [18,19,23,25]. High GPC3 ex-
pression tended to be correlated with the presence of
vascular invasion in all studies, and a statistical signifi-
cant correlation was observed in two studies [23,25].
Pooled data from all four studies showed a correlation
between high GPC3 expression and the presence of vas-
cular invasion (OR: 2.43, 95% CI: 1.23–4.82, p = 0.01;
Figure 3C).
Four studies reported data on GPC3 expression and
tumor size ≥ 5 cm in HCC [19,20,23,25]. High GPC3 ex-
pression tended to be correlated with the presence of
tumor size ≥ 5 cm in three studies, thought it was not sig-
nificant difference. Pooled data from all four studies showed
high GPC3 expression tended to be correlated with the
tumor size ≥ 5 cm (OR: 1.30, 95% CI: 0.88–1.93, p = 0.19;
Figure 3D).
Four studies reported data on GPC3 expression and
tumor multifocality in HCC [18,19,24,25]. High GPC3
expression tended to be correlated with the presence of
tumor multifocality in two studies. Pooled data from all
four studies showed high GPC3 expression tended to be
correlated with the presence of tumor multifocality (OR:







Shirakawal18 Yes NA NA
Yorita19 Yes 3.6 1.8-7.1
Su20 Yes NA NA
Yu21 NA NA NA
Wang23 NA NA NA
Chen24 Yes 2.27 1.14-4.51
Fu25 Yes 2.14 1.39-3.29
Liang26 NA NA NA
NA, not available; OS, overall survival; DFS, disease-free survival. Hazard ratio (HR); OSubgroup and sensitivity analysis
Subgroup analysis was performed to evaluate whether
the pooled estimates of OS, DFS, tumor grade, TNM
stage, vascular invasion, tumor size ≥ 5 cm and tumor
multifocality were different according to the GPC3 cut-off
values of 0%, 10%, 20%, and 25% of positive tumor cells by
IHC staining reported in the included studies. In addition,
subgroup analysis of studies that only used multivariate
statistical analysis was also conducted (Table 2). Sensitivity
analyses were performed by exclusion of the highest
weighted study in each pooled analysis (Table 3). Finally,
the results were all consistent with the above outcomes.
Publication bias
Publication bias estimate was mainly used to evaluate the
reliability of meta-analysis results, especially for those
showing statistical significance [27]. Publication bias was
assessed by using Egger’s test [28]. Statistical significance
was set at p <0.10. The results suggested evidence for pub-
lication bias in OS studies (p = 0.001), while it did not re-
veal significant publication bias in DFS studies (p = 0.404).
Discussion
HCC, one of the most aggressive malignant tumors, is
associated with poor prognosis despite significant im-
provement in surgical and locoregional therapies in past
few decades [20]. In recent years, considerable interest
has been focused on the mechanism of HCC metastasis/
recurrence after operation. However, the molecular fac-
tors associated with tumor progression and invasion of
HCC are still unknown.
From a clinical perspective, therefore, it is of great signifi-
cance to identify the most useful biomarkers for prognostic
prediction, which can help clinicians to adopt preventive
strategies for patients at high risk and further improve out-
come of patient with HCC. One potential candidate marker
for the progression and prognosis of HCC is GPC3. Al-
though the association of GPC3 with HCC has beenival in our included studies
OS
P HR 95% CI P
NA 1.84 1.04-3.25 0.034
0.0003 1.9 0.7-5.1 0.176
NA 1.905 1.063-3.415 0.030
NA NA NA NA
NA NA NA NA
0.02 NA NA NA
0.001 2.29 1.35-3.89 0.002
NA NA NA NA
dds ratio (OR); confidence intervals (CIs).
Table 3 Subgroup and Sensitivity analysis
Variables (cut-off value)* Number of study HR/OR 95% CI p I2
OS 6 1.96 1.51-2.55 0.000 0%
0% cut-off value Of GPC3 1 1.35 0.57-3.21 0.000 NA
10% cut-off value Of GPC3 3 1.84 1.25-2.71 0.002 0%
20% cut-off value Of GPC3 1 2.20 1.25-3.89 0.006 NA
25% cut-off value Of GPC3 1 2.29 1.35-3.89 0.002 NA
Exclusion of Liang et al. 5 2.04 1.55-2.68 0.000 0%
Studies with multivariate analysis 4 2.06 1.56-2.73 0.000 0%
Studies without multivariate analysis 2 1.43 0.70-2.91 0.32 0%
DFS 7 1.99 1.57-2.51 0.000 34%
0% cut-off value Of GPC3 0 NA NA NA NA
10% cut-off value Of GPC3 4 1.60 1.14-2.25 0.007 33%
20% cut-off value Of GPC3 1 3.60 1.81-7.14 0.000 NA
25% cut-off value Of GPC3 1 2.14 1.39-3.29 0.000 NA
Exclusion of Yorita et al. 6 1.83 1.43-2.36 0.000 14%
Studies with multivariate analyis 3 2.43 1.76-3.35 0.000 0%
Studies without multivariate analyis 4 1.58 1.12-2.22 0.010 29%
Tumor grade 4 3.30 2.04-5.33 0.000 34%
0% cut-off value Of GPC3 0 NA NA NA NA
10% cut-off value Of GPC3 2 5.55 1.92-16.06 0.002 0%
20% cut-off value Of GPC3 1 4.53 2.26-9.06 0.000 NA
25% cut-off value Of GPC3 1 1.61 0.70-3.73 0.26 NA
Exclusion of Yorita et al. l 3 2.45 1.26-4.78 0.008 39%
TNM stage 4 2.26 1.00-5.12 0.05 54%
0% cut-off value Of GPC3 0 NA NA NA NA
10% cut-off value Of GPC3 3 1.78 0.54-5.87 0.34 57%
20% cut-off value Of GPC3 1 3.40 1.87-6.18 0.000 NA
25% cut-off value Of GPC3 0 NA NA NA NA
Exclusion of Yorita et al. 3 1.78 0.54-5.87 0.34 57%
Vascular invasion 4 2.43 1.23-4.82 0.01 52%
0% cut-off value Of GPC3 0 NA NA NA NA
10% cut-off value Of GPC3 2 3.41 0.52-22.41 0.20 71%
20% cut-off value Of GPC3 1 3.34 1.85-6.05 0.000 NA
25% cut-off value Of GPC3 1 1.36 0.56-3.30 0.50 NA
Exclusion of Yorita et al. 3 2.11 0.81-5.49 0.13 52%
Tumor size≧ 5 cm 4 1.30 0.88-1.93 0.19 0%
0% cut-off value Of GPC3 0 NA NA NA NA
10% cut-off value Of GPC3 2 1.08 0.46-2.53 0.78 0%
20% cut-off value Of GPC3 1 1.19 0.67-2.11 0.56 NA
25% cut-off value Of GPC3 1 1.70 0.84-3.43 0.14 NA
Exclusion of Yorita et al. 3 1.41 0.82-2.42 0.21 0%
Tumor multifocality 4 2.42 0.94-6.23 0.07 72%
0% cut-off value Of GPC3 0 NA NA NA NA
10% cut-off value Of GPC3 2 4.59 0.41-51.05 0.21 83%
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Table 3 Subgroup and Sensitivity analysis (Continued)
20% cut-off value Of GPC3 1 1.06 0.53-2.12 0.86 NA
25% cut-off value Of GPC3 1 2.71 1.19-6.13 0.02 NA
Exclusion of Yorita et al. 3 3.50 1.09-11.18 0.03 66%
GPC3:glypican3; HR: hazard ratio; OR: odds ratios; CI: confidence interval; OS: overall survival; DFS: disease-free survival; NA: not available.
*High glypican-3 cut-off level was scored according to 0%, 10%, 20%, and 25% of the percentage of positive tumor cells by immunohistochemical staining.
A HR >1 implies a worse prognosis in the group with GPC3 overexpression; while an OR > 1 indicated higher probability for high tumor grade, later TNM stage,
the presence of vascular invasion,tumor size ≥ 5 cm and tumor multifocality in HCC with GPC3 overexpression.
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been fully analyzed. Considering that meta-analysis is a
valuable tool in biomarker validation [15], here we con-
ducted a meta-analysis to investigate the association be-
tween GPC3 and HCC progression and prognosis.
In this meta-analysis, we first assessed the association
of high GPC3 expression with OS and DFS in HCC pa-
tients. The pooled outcomes demonstrated that high
GPC3 expression significantly predicted poor OS and
DFS for patients with HCC (p = 0.000, p =0.000, respec-
tively). Although the results of the analysis are positive,
the reasons for different OS and DFS in HCC patients
with high or low GPC3 expression are not yet clear. It
should be noted that the poor prognosis of HCC was
usually correlated with tumor invasion and metastasis
[29]. Several studies have demonstrated that the GPC3
protein regulates HCC cells proliferation and growth, as
well as invasion via manipulating the canonical Wnt sig-
naling pathway, fibroblast growth factors, bone morpho-
genic proteins, transforming growth factor-β, and insulin
like growth factor-2 signaling pathways [30-32]. Ruan et al.
[33] reported that inhibition of glypican-3 expression via
RNA interference influences the growth and invasive
ability of the MHCC97-H human HCC cell line. These
may, in part, explain the aggressive malignant feature
of HCC modulated by GPC3.
Taking into account the association between tumor in-
vasion and GPC3 expression profile, in the present study,
we also carried out pooled analyses of the association be-
tween GPC3 expression and tumor pathological features.
The results indicated that high expression of GPC3 was
closely correlated with high tumor grade, late TNM stage
and the presence of vascular invasion. In summary, our
pooled outcomes supported the hyphothesis that GPC3
overexpression might promote invasion and metastasis of
HCC by direct or indirect mechanisms, which subse-
quently leaded to poor prognosis of HCC.
Our results should be interpreted cautiously since some
limitations exist in this present meta-analysis. First, the
potential risk of bias was a concern, since the positive re-
sults are more likely to be published than negative ones.
Though we tried to identify all relevant information, some
missing data are still inevitable, as reflecting by our publi-
cation bias evaluation. Moreover, total number of included
studies, as well as the total sample size was relativelysmall, which might influence the validity of our analysis to
some extent. Second, all these eight studies are based on
Asian population. It is believed that distinct site difference
exists in HCC between Western and Eastern populations.
In Asia, the majority HCC is hepatitis B (Chinese popu-
lation) or C (Japanese population) virus-related HCC
whereas alcohol-related or hepatitis C virus-related HCC
is the predominant cancer type in Western countries.
Therefore, the biologic features and behaviors of tumors
might be different between the two categories. As a result,
whether the GPC3 expression status and its function in
Western patients are identical with Asian ones is still un-
known, because there is no data about Western popu-
lations available till now. Third, in this study, GPC3
expression profiles were from tissue-based studies. In
view of that serum GPC3 level was an indirect marker of
its tissue expression, and it can be easily obtained and
measured at any time point. Thus, whether serum-based
GPC3 levels were superior to tissue-based GPC3 expres-
sion in predicting HCC invasion and prognosis remained
to be investigated by further studies. Fourth, the cut-off
value for defining high GPC3 expression has not been uni-
fied in these studies, which may lead to between-study
heterogeneity. Therefore, future large sample study to give
a definitive cut-off value of high GPC3 expression with
good sensitivity and specificity is needed. Fifth, since our
meta-analysis was carried out on the pooled data, strong
recommendations at an individual patient level could not
be obtained. Sixth, Several factors related to IHC such as
the type of antibody use, detection method, evaluation
method of results, inter-observer variation lead to the he-
terogeneity of IHC studies.
However, we addressed the issue of heterogeneity by
a rigorous methodologic approach. We included only
studies with a minimum sample size of 20 patients and
required at least 3 studies to carry out pooled analysis.
Furthermore, we also performed subgroup analysis and
sensitivity analysis to evaluate potential sources of bias
and the observed inter-study heterogeneity. Although we
were unable to carried out analysis with regard to cer-
tain potential relevant factors (such as patients’ body
mass index) due to the lack of data reported in many of
the included studies, the key finding of high GPC3 ex-
pression in the HCC tissue representing an indicator of
poor prognosis in patients with HCC was consistently
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throughout all subgroup analysis.
Conclusions
In summary, current available evidence supports the no-
tion of a strong prognostic effect of high GPC3 expression
in patients with HCC. It may be speculated that these
patients may potentially benefit from adjuvant therapy.
Further studies are required to verify the prognostic
significance of serum-based GPC3 levels, as a simple
method to monitor response to systemic therapy, tumor
progression and prognosis. Moreover, a definitive cut-off
value of high GPC3 expression based on future large sam-
ple study is recommended.
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